Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 6-(2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)pyridazin-3-amine
2. Bms-820836
1. Bms-820836
2. Liafensine [usan]
3. 1198790-53-2
4. R34id086z6
5. Liafensine (usan)
6. Liafensine [usan:inn]
7. Unii-r34id086z6
8. Bms 820836
9. Liafensine [inn]
10. Liafensine [who-dd]
11. Schembl1120067
12. Chembl2364614
13. Dtxsid60152610
14. Chebi:177531
15. Bdbm50459930
16. Db14878
17. D10443
18. Q18353685
19. (5)-6-(2-methyl-4-(naphthalen-2-yl)-1,2,3,4-tetrahydroisoquinolin-7-yl)pyridazin-3-amine
20. (s)-6-(2-methyl-4-(naphthalen-2-yl)-1,2,3,4-tetrahydroisoquinolin-7-yl)pyridazin-3-amine
21. 6-[(4s)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
22. 6-[(4s)-2-methyl-4-naphthalen-2-yl-3,4-dihydro-1h-isoquinolin-7-yl]pyridazin-3-amine
23. 3-pyridazinamine, 6-((4s)-1,2,3,4-tetrahydro-2-methyl-4-(2-naphthalenyl)-7-isoquinolinyl)-
24. 6-((4s)-2-methyl-4-(naphthalen-2-yl)-1,2,3,4-tetrahydroisoquinolin-7-yl)pyridazin-3-amine
| Molecular Weight | 366.5 g/mol |
|---|---|
| Molecular Formula | C24H22N4 |
| XLogP3 | 3.7 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 2 |
| Exact Mass | 366.18444672 g/mol |
| Monoisotopic Mass | 366.18444672 g/mol |
| Topological Polar Surface Area | 55 Ų |
| Heavy Atom Count | 28 |
| Formal Charge | 0 |
| Complexity | 525 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Liafensine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Liafensine, including repackagers and relabelers. The FDA regulates Liafensine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Liafensine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Liafensine supplier is an individual or a company that provides Liafensine active pharmaceutical ingredient (API) or Liafensine finished formulations upon request. The Liafensine suppliers may include Liafensine API manufacturers, exporters, distributors and traders.
Liafensine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Liafensine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Liafensine GMP manufacturer or Liafensine GMP API supplier for your needs.
A Liafensine CoA (Certificate of Analysis) is a formal document that attests to Liafensine's compliance with Liafensine specifications and serves as a tool for batch-level quality control.
Liafensine CoA mostly includes findings from lab analyses of a specific batch. For each Liafensine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Liafensine may be tested according to a variety of international standards, such as European Pharmacopoeia (Liafensine EP), Liafensine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Liafensine USP).
LOOKING FOR A SUPPLIER?
